The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Kathleen Colleran, University of New Mexico
ClinicalTrials.gov Identifier:
NCT00656331
First received: April 7, 2008
Last updated: April 11, 2012
Last verified: April 2012
  Purpose

The purpose of this study is to compare the effects of the cholesterol medication taken with each blood pressure medication alone on heart disease risk factors including blood pressure, cholesterol, inflammation, blood sugar control, blood vessal function, and other heart disease risk factors.


Condition Intervention
Hypertension
Drug: Amlodipine and Hydrocholorothiazide

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications: A Comparison of Amlodipine and Hydrochlorothiazide

Resource links provided by NLM:


Further study details as provided by University of New Mexico:

Primary Outcome Measures:
  • PAI-1 [ Time Frame: study completion ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: August 2005
Estimated Study Completion Date: June 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Amlodipine
Drug: Amlodipine and Hydrocholorothiazide
Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
Active Comparator: 2
HCTZ
Drug: Amlodipine and Hydrocholorothiazide
Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • mild hypertension and high cholesterol

Exclusion Criteria:

  • diabetes and heart disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00656331

Locations
United States, New Mexico
UNMHSC
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Investigators
Principal Investigator: Kathleen Colleran, MD University of New Mexico
  More Information

No publications provided

Responsible Party: Kathleen Colleran, Professor of Medicine, University of New Mexico
ClinicalTrials.gov Identifier: NCT00656331     History of Changes
Other Study ID Numbers: 05-106
Study First Received: April 7, 2008
Last Updated: April 11, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Hydrochlorothiazide
Amlodipine
Atorvastatin
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Calcium Channel Blockers
Vasodilator Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Enzyme Inhibitors
Lipid Regulating Agents

ClinicalTrials.gov processed this record on July 29, 2014